WHAT IS CLAIMED IS:

1. Use of a monoclonal anti-beta7 antibody in the manufacture of a medicament for treating a gastrointestinal inflammatory disorder, wherein the anti-beta7 antibody is to be administered subcutaneously at a flat dose of between about 50 mg and about 450 mg, wherein the anti-beta7 antibody comprises three heavy chain hypervariable region (HVR-H1-H3) sequences and three light chain hypervariable region (HVR-L1-L3) sequences, wherein:

(i) HVR-L1 comprises SEQ ID NO:9;
(ii) HVR-L2 comprises SEQ ID NO:2;
(iii) HVR-L3 comprises SEQ ID NO:3;
(iv) HVR-H1 comprises SEQ ID NO:4;
(v) HVR-H2 comprises SEQ ID NO:5; and
(vi) HVR-H3 comprises SEQ ID NO: 19.

2. The use of claim 1, wherein ~~the anti-beta7 antibody is to be administered at a flat dose between about 50 mg and about 450 mg, wherein optionally~~ the flat dose is selected from the group consisting of about 50 mg, about 100 mg, about 150 mg, about 200 mg, about 300 mg, about 350 mg, about 400 mg, about 420 mg, and about 450 mg, wherein optionally the anti-beta7 antibody is to be administered once every week, or once or every two weeks, or once every four weeks, or once every six weeks, or once every eight weeks, and wherein optionally the anti-beta7 antibody is to be administered for a period of two months, or three months, or six months, or 12 months, or 18 months, or 24 months, or for the lifetime of the patient.

3. The use of claim 1, wherein the patient is a human.

4. The use of claim 1, wherein the gastrointestinal inflammatory disorder is an inflammatory bowel disease, and wherein optionally the inflammatory bowel disease is ulcerative colitis or Crohn's disease.

5. The use of claim 1, wherein the anti-beta7 antibody is selected from a chimeric antibody, a human antibody, and a humanized antibody.

6. The use of claim 5, wherein the anti-beta7 antibody is a humanized antibody.

7. The use of claim 1, wherein the anti-beta7 antibody is to be administered at a flat dose of about 100 mg or about 300 mg every four weeks, wherein the patient suffers from ulcerative colitis, and wherein the patient experiences mucosal healing or a reduced rate of flare over time.

8. Use of a monoclonal anti-beta7 antibody in the manufacture of a medicament for treating a gastrointestinal inflammatory disorder, wherein the anti-beta7 antibody is to be administered a first loading dose and at least one subsequent maintenance dose, wherein ~~each of~~ the first loading dose is a flat dose of between about 400 mg and about 450 mg and the at least one maintenance dose is a flat dose of between about 50 mg and about 350 mg, each of the first loading dose and the at least one maintenance dose is to be administered subcutaneously ~~at a flat dose~~, wherein the anti-beta7 antibody comprises three heavy chain hypervariable region (HVR-H1-H3) sequences and three light chain hypervariable region (HVR-L1-L3) sequences, wherein:

(i) HVR-L1 comprises SEQ ID NO:9;
(ii) HVR-L2 comprises SEQ ID NO:2;
(iii) HVR-L3 comprises SEQ ID NO:3;

(iv) HVR-H1 comprises SEQ ID NO:4;
(v) HVR-H2 comprises SEQ ID NO:5; and
(vi) HVR-H3 comprises SEQ ID NO:19.

~~9. The use of claim 8, wherein the loading dose is between about 400 mg and about 450 mg and the maintenance dose is between about 50 mg and about 350 mg.~~

~~10~~9. The use of claim ~~9~~8, wherein the loading dose is about 400 mg, or about 420 mg, or about 430 mg, or about 450 mg.

~~11~~10. The use of claim ~~9~~8, wherein the maintenance dose is about 50 mg, or about 100 mg, or about 150 mg, or about 200 mg, or about 300 mg, or about 350 mg.

~~12~~11. The use of claim ~~9~~8, wherein the loading dose and the maintenance dose are selected from the group consisting of:

(i) the loading dose is about 400 mg and the maintenance dose is about 50 mg, or about 100 mg, or about 150 mg, or about 200 mg, or about 300 mg, or about 350 mg;

(ii) the loading dose is about 420 mg and the maintenance dose is about 50 mg, or about 100 mg, or about 150 mg, or about 200 mg, or about 300 mg, or about 350 mg;

(iii) the loading dose is about 430 mg and the maintenance dose is about 50 mg, or about 100 mg, or about 150 mg, or about 200 mg, or about 300 mg, or about 350 mg;

(iv) the loading dose is about 450 mg and the maintenance dose is about 50 mg, or about 100 mg, or about 150 mg, or about 200 mg, or about 300 mg, or about 350 mg;

(v) the loading dose is about 400 mg, or about 420 mg, or about 430 mg, or about 450 mg and the maintenance dose is about 50 mg;

(vi) the loading dose is about 400 mg, or about 420 mg, or about 430 mg, or about 450 mg and the maintenance dose is about 100 mg;

(vii) the loading dose is about 400 mg, or about 420 mg, or about 430 mg, or about 450 mg and the maintenance dose is about 150 mg;

(viii) the loading dose is about 400 mg, or about 420 mg, or about 430 mg, or about 450 mg and the maintenance dose is about 200 mg;

(ix) the loading dose is about 400 mg, or about 420 mg, or about 430 mg, or about 450 mg and the maintenance dose is about 300 mg; and

(x) the loading dose is about 400 mg, or about 420 mg, or about 430 mg, or about 450 mg and the maintenance dose is about 350 mg.

~~13~~12. The use of claim ~~10~~9, wherein the loading dose is about 420 mg.

~~14~~13. The use of claim ~~10~~9, wherein the loading dose is about 450 mg.

~~15~~14. The use of claim ~~13~~12 or ~~14~~13, wherein the maintenance dose is about 350 mg.

~~16~~15. The use of claim 8, wherein the first maintenance dose is to be administered one day, or one week, or two weeks, or four weeks after the loading dose, or on the same day as the loading dose.

~~17~~16. The use of claim ~~16~~15, wherein the second and each subsequent maintenance dose is to be administered every two weeks, or every four weeks, or every eight weeks.

~~18~~17. The use of claim 8, wherein the first maintenance dose is to be administered two weeks after the loading dose, the second maintenance dose is to be administered two weeks after the first maintenance dose, and each subsequent maintenance dose is to be administered every four weeks.

~~19~~18. The use of claim 8, wherein the anti-beta7 antibody is to be administered for a period of two months, or three months, or six months, or 12 months, or 18 months, or 24 months, or for the lifetime of the patient.

~~20~~19. The use of claim 8, wherein the patient is a human.

~~21~~20. The use of claim 8, wherein the gastrointestinal inflammatory disorder is an inflammatory bowel disease, and wherein optionally the inflammatory bowel disease is ulcerative colitis or Crohn's disease.

~~22~~21. The use of claim 8, wherein the anti-beta7 antibody is selected from a chimeric antibody, a human antibody, and a humanized antibody.

~~23~~22. The use of claim ~~22~~21, wherein the anti-beta7 antibody is a humanized antibody.

~~24~~23. The use according to any one of claims 1-~~23~~22, wherein the anti-beta7 antibody is to be administered with at least one additional compound selected from 5- aminosalicylic acid (5-ASA), azathioprine (AZA), 6-mercaptopurine (6-MP), and methotrexate.

~~25~~24. The use according to any one of claims 1-~~23~~22, wherein the patient previously failed at least one biological agent, and wherein optionally the biological agent is selected from adalimumab, etanercept, infliximab, golimumab, certolizumab pegol, natalizumab, and vedolizumab.

~~26~~25. The use according to any one of claims 1-~~23~~22, wherein the anti-beta7 antibody to be administered with a self-inject device, and wherein optionally the self-inject device is selected from a prefilled syringe, microneedle device, autoinjector device and needle-free injection device.

~~27~~26. Use of a monoclonal anti-beta7 antibody in the manufacture of a medicament for inducing remission in a patient suffering from ulcerative colitis, wherein the anti-beta7 antibody is to be administered subcutaneously at a flat dose of either about 100 mg or about 300 mg every four weeks, wherein the anti-beta7 antibody comprises three heavy chain hypervariable region (HVR-H1-H3) sequences and three light chain hypervariable region (HVR-L1-L3) sequences, wherein:

(i) HVR-L1 comprises SEQ ID NO:9;
(ii) HVR-L2 comprises SEQ ID NO:2;
(iii) HVR-L3 comprises SEQ ID NO:3;
(iv) HVR-H1 comprises SEQ ID NO:4;
(v) HVR-H2 comprises SEQ ID NO:5; and
(vi) HVR-H3 comprises SEQ ID NO: 19.

~~28~~27. The use of claim ~~27~~26, further comprising determining a Mayo Clinic Score and Mayo Clinic subscores, wherein the patient is determined to have an absolute Mayo Clinic Score < 2 and no

individual subscore >1, and wherein optionally remission is induced at least by week 10 following the first administration of the anti-beta7 antibody~~etrolizumab~~.

~~29~~28. Use of a monoclonal anti-beta7 antibody in the manufacture of a medicament for inducing sustained remission in a patient suffering from ulcerative colitis, wherein the anti-beta7 antibody is to be administered subcutaneously at a flat dose of either about 100 mg or about 300 mg every four weeks, wherein remission is retained for a period of 8 weeks following induction of remission, or a period of 30 weeks following induction of remission, or a period of 50 weeks following induction of remission, or a period of 54 weeks or more following induction of remission, wherein the anti-beta7 antibody comprises three heavy chain hypervariable region (HVR-H1-H3) sequences and three light chain hypervariable region (HVR-L1-L3) sequences, wherein:

(i) HVR-L1 comprises SEQ ID NO:9;
(ii) HVR-L2 comprises SEQ ID NO:2;
(iii) HVR-L3 comprises SEQ ID NO:3;
(iv) HVR-H1 comprises SEQ ID NO:4;
(v) HVR-H2 comprises SEQ ID NO:5; and
(vi) HVR-H3 comprises SEQ ID NO: 19.

~~30~~29. The use of claim ~~29~~28, wherein the remission is steroid-free remission, and wherein optionally the steroid-free remission is for 20 weeks following induction of remission, or for 24 weeks or longer following induction of remission.